<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35198464</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2229-5178</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>13</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Season>Jan-Feb</Season>
            </PubDate>
          </JournalIssue>
          <Title>Indian dermatology online journal</Title>
          <ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study.</ArticleTitle>
        <Pagination>
          <StartPage>23</StartPage>
          <EndPage>31</EndPage>
          <MedlinePgn>23-31</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.4103/idoj.idoj_530_21</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Case reviews of severe cutaneous adverse drug reactions (ADRs) such as SJS/TEN provide useful insights for clinical characteristics, putative drugs, and management protocols.</AbstractText>
          <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Medical charts of 62 (m:f- 20:42) patients with SJS/TEN hospitalized between 2010 and 2019 were analyzed retrospectively for clinical attributes, putative drugs and their indications, extracutaneous complications, and therapeutic outcome. The diagnosis was clinical based on established criteria. WHO-UMC scale for reporting ADR and ALDEN algorithm score were used for causality assessment. Therapies were customized based on in-house resources and affordability.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Cases included were SJS (41.9%), SJS/TEN overlap (33.9%), and TEN (24.2%) aged 4-85 years. Complications included transaminitis (69.4%), lymphadenopathy (15.5%), septicemia (11.3%), and wound infections (4.8%). Aromatic anticonvulsants (37.1%), disease-modifying antirheumatic drugs (25.8%), antiretroviral drugs (12.9%), non-steroidal anti-inflammatory drugs (8.1%), antimicrobials (4.8%), and trihexyphenidyl (3.2%) were major putative drugs. The mean latent period was 16.6 days. The observed 8% mortality was because of primary comorbidities or multiorgan failure. Addition of fresh blood transfusion (BT, n = 11) or IVIg (n = 7) to systemic corticosteroids showed early relief in skin tenderness, improvement in general condition, and re-epithelialization. Only 16% of patients developed sequelae.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Aromatic anticonvulsants, allopurinol, nevirapine, cotrimoxazole, paracetamol, and diclofenac remain the most implicated drugs. Sulfasalazine, leflunomide, ethambutol, and trihexyphenidyl were uncommon additions. A short course of high-dose dexamethasone in the early stage was useful. Addition of BT or IVIg provided rapid relief. Preexisting HIV disease, kidney disease, and sepsis remain important for in-hospital deaths. Retrospective study design and small number of cases remain major limitations.</AbstractText>
          <CopyrightInformation>Copyright: © 2022 Indian Dermatology Online Journal.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Manvi</LastName>
            <ForeName>Sujaya</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Venereology and Leprosy, Dr. Rajendra Prasad Government Medical College, Kangra (Tanda), Himachal Pradesh, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mahajan</LastName>
            <ForeName>Vikram K</ForeName>
            <Initials>VK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Venereology and Leprosy, Dr. Rajendra Prasad Government Medical College, Kangra (Tanda), Himachal Pradesh, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mehta</LastName>
            <ForeName>Karaninder S</ForeName>
            <Initials>KS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Venereology and Leprosy, Dr. Rajendra Prasad Government Medical College, Kangra (Tanda), Himachal Pradesh, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chauhan</LastName>
            <ForeName>Pushpinder S</ForeName>
            <Initials>PS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Venereology and Leprosy, Dr. Rajendra Prasad Government Medical College, Kangra (Tanda), Himachal Pradesh, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vashist</LastName>
            <ForeName>Sanket</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Venereology and Leprosy, Dr. Rajendra Prasad Government Medical College, Kangra (Tanda), Himachal Pradesh, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Ravinder</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Venereology and Leprosy, Dr. Rajendra Prasad Government Medical College, Kangra (Tanda), Himachal Pradesh, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kumar</LastName>
            <ForeName>Prabal</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Venereology and Leprosy, Dr. Rajendra Prasad Government Medical College, Kangra (Tanda), Himachal Pradesh, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Indian Dermatol Online J</MedlineTA>
        <NlmUniqueID>101586880</NlmUniqueID>
        <ISSNLinking>2229-5178</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Allopurinol</Keyword>
        <Keyword MajorTopicYN="N">HIV disease</Keyword>
        <Keyword MajorTopicYN="N">SCORTEN</Keyword>
        <Keyword MajorTopicYN="N">Stevens–Johnson syndrome</Keyword>
        <Keyword MajorTopicYN="N">anticonvulsants</Keyword>
        <Keyword MajorTopicYN="N">corticosteroids</Keyword>
        <Keyword MajorTopicYN="N">efavirenz</Keyword>
        <Keyword MajorTopicYN="N">intravenous immunoglobulin</Keyword>
        <Keyword MajorTopicYN="N">leflunomide</Keyword>
        <Keyword MajorTopicYN="N">nevirapine</Keyword>
        <Keyword MajorTopicYN="N">physiological hyperuricemia</Keyword>
        <Keyword MajorTopicYN="N">septicemia</Keyword>
        <Keyword MajorTopicYN="N">severe mucocutaneous adverse drug reactions</Keyword>
        <Keyword MajorTopicYN="N">sodium valproate</Keyword>
        <Keyword MajorTopicYN="N">sulfasalazine</Keyword>
        <Keyword MajorTopicYN="N">toxic epidermal necrolysis</Keyword>
        <Keyword MajorTopicYN="N">trihexyphenidyl</Keyword>
      </KeywordList>
      <CoiStatement>There are no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>5</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35198464</ArticleId>
        <ArticleId IdType="pmc">PMC8809144</ArticleId>
        <ArticleId IdType="doi">10.4103/idoj.idoj_530_21</ArticleId>
        <ArticleId IdType="pii">IDOJ-13-23</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Mockenhaupt M. The current understanding of Stevens– Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011;7:803–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22014021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu M, Gao Y, Pan Y, Li W, Liao W, Wang G, et al.  Recovered patients with Stevens Johson syndrome and toxic epidermal necrolysis maintain long lived IFN-c and sFasL memory response. PLoS One. 2012;7:e45516. doi: 10.1371/journal.pone.0045516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3445504</ArticleId>
            <ArticleId IdType="pubmed">23029066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: Our current understanding. Allergol Int. 2006;55:9–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17075281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mulvey JM, Padowitz A, Lindley-Jones M, Nickels R. Mycoplasma pneumoniae associated with Stevens Johnson syndrome. Anaesth Intensive Care. 2007;35:414–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17591139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>BastujiGarin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8420497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carrasquillo OY, Santiago-Vazquez M, Cardona R, Cruz-Manzano M, Figueroa LD. Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective descriptive study. Int J Dermatol. 2019;58:1293–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31166019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernando SL. The management of toxic epidermal necrolysis. Australas J Dermatol. 2012;55:165–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22881464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahajan VK, Handa S. Patch testing in cutaneous adverse drug reactions: Methodology, interpretation and clinical relevance. Indian J Dermatol Venereol Leprol. 2013;79:836–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24177628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3018455</ArticleId>
            <ArticleId IdType="pubmed">21162721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17805350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gravante G, Delogu D, Marianetti M, Esposito G, Montone A. Toxic epidermal necrolysis and Steven-Johnson syndrome in oncologic patients. Eur Rev Med Pharmacol Sci. 2007;11:269–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17876963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al.  HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008;9:1617–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19018717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta LK, Martin AM, Agarwal N, D'Souza P, Das S, Kumar R, et al.  Guidelines for the management of Stevens– Johnson syndrome/toxic epidermal necrolysis: An Indian perspective. Indian J Dermatol Venereol Leprol. 2016;82:603–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27716721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee HY, Tay LK, Thirumoorthy T, Pang SM. Cutaneous adverse drug reactions in hospitalized patients. Singapore Med J. 2016;51:767–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21103811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, et al.  ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: Comparison with case-control analysis. Clin Pharmacol Ther. 2010;88:60–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20375998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thakur V, Vinay K, Kumar S, Choudhary R, Kumar A, Parsad D, et al.  Factors predicting the outcome of Stevens–Johnson syndrome and toxic epidermal necrolysis: A 5-year retrospective study. Indian Dermatol Online J. 2021;12:258–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8088174</ArticleId>
            <ArticleId IdType="pubmed">33959522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh , G , Mitra B, Arora S, Akhoon N, Verma R, Sharma P, et al.  A retrospective, 5-year, clinicoepidemiological study of severe cutaneous adverse reactions (SCARs) Int J Dermatol. 2021;60:579–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33454956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol. 2005;5:309–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15985812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64:1134–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15824335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirsch LJ, Weintraub D, Buchsbaum R, Spencer HT, Straka T, Hager M, et al.  Predictors of lamotrigine associated rash. Epilepsia. 2006;47:318–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16499755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaur S, Dogra A. Toxic epidermal necrolysis due to concomitant use of lamotrigine and valproic acid. Indian J Dermatol. 2013;58:406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3778793</ArticleId>
            <ArticleId IdType="pubmed">24082198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahatme N, Narasimharao R. A study of clinical patterns and causative agents of adverse cutaneous drug reactions. Indian J Drugs Dermatol. 2016;2:13.</Citation>
        </Reference>
        <Reference>
          <Citation>Oshikoya KA, Ogunyinka IA, Ogar CK, Abiola A, Ibrahim A, Oreagba IA. Severe cutaneous adverse drug reactions manifesting as Stevens-Johnson syndrome and toxic epidermal necrolysis reported to the national pharmacovigilance center in Nigeria: A database review from 2004 to 2017. Ther Adv Drug Saf. 2020;11:2042098620905998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7016315</ArticleId>
            <ArticleId IdType="pubmed">32110375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaudhary SC, Atam V, Gupta A, Arya R, Soni D. Ethambutol induced toxic epidermal necropysis. J Assoc Physicians India. 2011;59:391–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21751601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, et al.  EuroSCAR Study Group. Allopurinol is the most common cause of Stevens Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58:25–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17919772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: Results from the UK General Practice Research Database (GPRD) Rheumatology (Oxford) 2005;44:1038–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15870145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warren KJ, Boxwell DE, Kim NY, Drolet BA. Nevirapine-associated Stevens-Johnson syndrome. Lancet. 1998;351:67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9492778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1998;20:1071–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9916603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003;83:1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12636014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paik S, Pal A, Sen S, Pramanick N, Tripathi SK. A suspected case of Efavirenz-induced Stevens–Johnson syndrome. Drug Saf Case Rep. 2015;2:15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5005653</ArticleId>
            <ArticleId IdType="pubmed">27747727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colebunders R, Vanwolleghem T, Meurrens P, Moerman F. Efavirenz-associated Stevens-Johnson Syndrome. Infection. 2004;32:306–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15624898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, et al.  Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis. JAMA Dermatol. 2017;153:514–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5817620</ArticleId>
            <ArticleId IdType="pubmed">28329382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mangla K, Rastogi S, Goyal P, Solanki RB, Rawal RC. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: An open uncontrolled study. Indian J Dermatol Venereol Leprol. 2005;71:398–400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16394480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>AlMutairi N, Arun J, Osama NE, Amr Z, Mazen AS, Ibtesam el-A, et al.  Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol. 2004;43:847–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15533072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami experience. Arch Dermatol. 2003;139:39–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12533162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17919775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: A systematic review and meta-analysis. Br J Dermatol. 2012;167:424–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22458671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, et al.  Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: Multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139:26–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12533160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stella M, Clemente A, Bollero D, Risso D, Dalmasso P. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): Experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns. 2007;33:452–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17475410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jagadeesan S, Sobhanakumari K, Sadanandan SM, Ravindran S, Divakaran MV, Skaria L, et al.  Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: A prospective comparative open-labelled study of 36 cases. Indian J Dermatol Venereol Leprol. 2013;79:506–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23760320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhar S. Role of blood transfusion in the management of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) Indian J Dermatol Venereol Leprol. 1998;64:250–1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20921787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson Syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136:1387–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27039263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, et al.  Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133:1197–204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23389396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequalae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69:187.e1–16. quiz 203-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23866879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10951229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guégan S, Bastuji-Garin S, Poszepczynska-Guigné E, Roujeau JC, Revuz J. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol. 2006;126:272–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16374461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Micheletti RG, ChiesaFuxench Z, Noe MH, Stephen S, Aleshin M, Agarwal A, et al.  Stevens-Johnson syndrome/toxic epidermal necrolysis: A multicenter retrospective study of 377 adult patients from the United States. J Invest Dermatol. 2018;138:2315–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29758282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imahara SD, Holmes JH, 4th, Heimbach DM, Engrav LE, Honari S, Klein MB, et al.  SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res. 2006;27:270–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16679892</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
